

Marcel Rieker

Targeted Combination Therapy: Discovery and
Evaluation of Synergistic Anticancer Effects of
Anti-HER2-Duocarmycin Antibody-Drug
Conjugates Combined with ATR Inhibitors

**Targeted Combination Therapy: Discovery and
Evaluation of Synergistic Anticancer Effects of Anti-
HER2-Duocarmycin Antibody-Drug Conjugates
Combined with ATR Inhibitors**



TECHNISCHE
UNIVERSITÄT
DARMSTADT

vom Fachbereich Chemie
der Technischen Universität Darmstadt

zur Erlangung des Grades
Doctor rerum naturalium (Dr. rer. nat.)

Dissertation

Von

Marcel Rieker, M. Sc.
aus Darmstadt

Erstgutachter: Prof. Dr. Harald Kolmar

Zweitgutachter: Prof. Dr. Felix Hausch

Darmstadt 2018

Tag der Einreichung: 31. August 2018

Tag der mündlichen Prüfung: 15. Oktober 2018

Berichte aus der Biochemie

Marcel Rieker

**Targeted Combination Therapy:
Discovery and Evaluation of Synergistic
Anticancer Effects of Anti-HER2-Duocarmycin
Antibody-Drug Conjugates Combined
with ATR Inhibitors**

D 17 (Diss. TU Darmstadt)

Shaker Verlag
Aachen 2019

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <http://dnb.d-nb.de>.

Zugl.: Darmstadt, Techn. Univ., Diss., 2018

Copyright Shaker Verlag 2019

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers.

Printed in Germany.

ISBN 978-3-8440-6478-0

ISSN 1434-5536

Shaker Verlag GmbH • P.O. BOX 101818 • D-52018 Aachen

Phone: 0049/2407/9596-0 • Telefax: 0049/2407/9596-9

Internet: www.shaker.de • e-mail: info@shaker.de

Die vorliegende Arbeit wurde unter der Leitung von Herrn Prof. Dr. Harald Kolmar am Clemens-Schöpf-Institut für Organische Chemie und Biochemie der Technischen Universität Darmstadt sowie bei Merck KGaA in Darmstadt von Oktober 2015 bis Oktober 2018 angefertigt.

Publications or patents derived from the presented work

Parts of this work have been published or are currently under review.

Publications to related projects

Pirzer, T., Becher, K., Rieker, M., Meckel, T., Mootz, H. D., & Kolmar, H. (2018). Generation of potent anti-HER1/2 immunotoxins by protein ligation using split inteins. *ACS Chemical Biology*, *13*(8), 2058–2066.

1. Content

1.....Content	I
2.....Abstract	1
1.....Zusammenfassung	3
2.....Introduction	5
2.1. Cancer Prevalence	5
2.2. Enabling Characteristics of Tumor Development and Hallmarks of Cancer	6
2.3. Short History of Cancer Therapy	10
2.4. Cancer Therapy - Drug Combinations	13
2.5. Cancer Therapy - Antibody-Drug Conjugates	16
2.5.1. Therapeutic Development of Duocarmycin	27
2.6. DNA Damage and Replication Response	32
2.6.1. ATR – Key Kinase in Replication Stress Response	35
2.6.2. ATM and DNA-PK – Central Kinases in Double-Strand Break Repair	40
2.7. Objective of this Work	41
3.....Methods and Materials	43
3.1. Reagents	43
3.2. Commercially available systems	55
3.3. Consumable material	56
3.4. Devices	56
3.5. Buffer and Solutions	57
3.6. Antibody Expression	58
3.7. Transformation	58
3.8. Plasmid Amplification	59
3.9. ADC Generation	59
3.10. Sortase A-Mediated Conjugation Reaction	61
3.11. Protein A Chromatography	62
3.12. Preparative SEC	62
3.13. Analytical HIC	63

3.14.	Analytical SEC	64
3.15.	Buffer Change	64
3.16.	Thawing of Mammalian Cancer Cells	64
3.17.	Culturing of Mammalian Cancer Cells	65
3.18.	Curve-Shift Assays	65
3.19.	Dose-Matrix Assays	66
3.20.	Knock-Down Experiments	67
3.21.	Statistical Analysis	67
3.22.	Xenograft Experiment	67
3.23.	Cellular CHK1 Phosphorylation Inhibition	68
4.....	Results	71
4.1.	Screening for Synergistic Drug Combination Partner for Duocarmycins	71
4.2.	Synergistic Drug Combinations of a Duocarmycin library with ATR inhibitor AZD6738	79
4.3.	Biological Activity of ATR Inhibitors	82
4.4.	ADC generation	86
4.4.1.	Generation of Duocarmycin-Bearing ADCs	86
4.4.2.	Generation of Control ADCs	90
4.5.	Cytotoxicity of Duocarmycin-Based ADCs	91
4.6.	Synergy of Duocarmycin-ADCs with ATRi	95
4.6.1.	Synergy of Combinations of α HER2-Duocarmycin ADCs and ATRi	95
4.6.2.	Synergy of Combinations of α EGFR-Duocarmycin ADCs and ATRi	100
4.6.3.	Dose-Reduction of α HER2-Duocarmycin Combinations with ATRi	101
4.6.4.	Potential Effects of Glycoprotein Binding-Duocarmycin DM ADC when Combined with ATRi	111
4.7.	In Depth Investigation of Drug Combinations of ATRi with Duocarmycin	112
4.8.	<i>In vivo</i> Efficacy and Tolerability of α HER2-6 Combination with ATR Inhibitors AZD6738 and ATRi 1	122
4.9.	Bleomycin A5-ADCs	124
4.9.1.	Generation of Bleomycin A5-Bearing ADCs	124

4.9.2.	Cytotoxicity of Bleomycin A5-Based ADCs	125
4.9.3.	Synergistic Effects of Bleomycin A5-ADC Combinations with DDRi	127
4.9.4.	Potential Effects of Bleomycin A5-ADC Combined with NU7441 or KU-55933	128
5.....	Discussion	129
5.1.	Screening for a Synergistic Drug Combination Partner for Duocarmycin	129
5.2.	Impact of Duocarmycin Structure on Synergistic Effects	129
5.3.	ADC-Generation to Modulate the Therapeutic Window of Duocarmycin	132
5.4.	Synergistic Effects of Combinations of Duocarmycin-ADCs with ATRi	135
5.5.	Therapeutic Relevance of the Synergistic Combination of Duocarmycin-ADCs with ATR Inhibitors	138
5.6.	Mechanism of ATR-Mediated Sensitization for Duocarmycin Treatment	142
5.7.	DNA-PK Inhibition for ADC Combination Therapy	147
6.....	Outlook	149
6.1.	Biomarker Identification and Refinement of Proposed Mechanism of Synergy	149
6.2.	Improvement of Anti-Tumor Effects of Duocarmycin-ADCs Combined with ATR Inhibitors	150
7.....	Appendix	1
7.1.	Sources	24
7.2.	List of figures	38
7.3.	Abbreviations	42
7.4.	Acknowledgements	48
8.....	Affirmations	51